Invention Grant
- Patent Title: Substituted imidazoles as PLXDC2 ligands
-
Application No.: US17488984Application Date: 2021-09-29
-
Publication No.: US11597717B2Publication Date: 2023-03-07
- Inventor: Josep Bassaganya-Riera , Andrew Leber , Raquel Hontecillas , Nuria Tubau-Juni
- Applicant: Landos Biopharma, Inc.
- Applicant Address: US VA Blacksburg
- Assignee: Landos Biopharma, Inc.
- Current Assignee: Landos Biopharma, Inc.
- Current Assignee Address: US VA Blacksburg
- Agency: DeWitt LLP
- Agent Daniel A. Blasiole
- Main IPC: A61K31/4164
- IPC: A61K31/4164 ; C07D233/90 ; C07D401/12 ; A61P37/00 ; A61P19/02 ; A61P35/04 ; C07D405/12

Abstract:
Provided are compounds of Formula Y-Z: The compounds target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
Public/Granted literature
- US20220017488A1 PLXDC2 LIGANDS Public/Granted day:2022-01-20
Information query